@article{0c0e075bf52d42da838fcb6bdb36fdf6,
title = "Securing sustainable funding for viral hepatitis elimination plans",
abstract = "The majority of people infected with chronic hepatitis C virus (HCV) in the European Union (EU) remain undiagnosed and untreated. During recent years, immigration to EU has further increased HCV prevalence. It has been estimated that, out of the 4.2 million adults affected by HCV infection in the 31 EU/ European Economic Area (EEA) countries, as many as 580 000 are migrants. Additionally, HCV is highly prevalent and under addressed in Eastern Europe. In 2013, the introduction of highly effective treatments for HCV with direct-acting antivirals created an unprecedented opportunity to cure almost all patients, reduce HCV transmission and eliminate the disease. However, in many settings, HCV elimination poses a serious challenge for countries' health spending. On 6 June 2018, the Hepatitis B and C Public Policy Association held the 2nd EU HCV Policy summit. It was emphasized that key stakeholders should work collaboratively since only a few countries in the EU are on track to achieve HCV elimination by 2030. In particular, more effort is needed for universal screening. The micro-elimination approach in specific populations is less complex and less costly than country-wide elimination programmes and is an important first step in many settings. Preliminary data suggest that implementation of the World Health Organization (WHO) Global Health Sector Strategy on Viral Hepatitis can be cost saving. However, innovative financing mechanisms are needed to raise funds upfront for scaling up screening, treatment and harm reduction interventions that can lead to HCV elimination by 2030, the stated goal of the WHO.",
keywords = "burden, c virus-infection, care, cost, disease, elimination, health policy, high-risk populations, outcomes, prevention, strategies, surveillance, treatment, viral hepatitis, STRATEGIES, COST, C VIRUS-INFECTION, DISEASE, OUTCOMES",
author = "A. Hatzakis and J.V. Lazarus and E. Cholongitas and R. Baptista-Leite and C. Boucher and C.S. Busoi and S. Deuffic-Burban and J. Chhatwal and G. Esmat and S. Hutchinson and M.M. Malliori and M. Maticic and A. Mozalevskis and F. Negro and G.A. Papandreou and G.V. Papatheodoridis and M. Peck-Radosavljevic and H. Razavi and T. Reic and E. Schatz and N. Tozun and Z. Younossi and M.P. Manns",
note = "Funding Information: Angelos Hatzakis has received research grants from AbbVie, Gilead and MSD, unrestricted grants from AbbVie, BMS, Gilead, MSD and Novartis, has served as an advisor/lecturer for BMS, Gilead, MSD, AbbVie and is co‐chair of the Hepatitis B and C Public Policy Association supported by AbbVie, BMS, Gilead, MSD. Jeffrey V. Lazarus has received grants from AbbVie, Gilead Sciences and MSD outside of the submitted work. Evangelos Cholongitas has served as a speaker, a consultant and an advisory board member for Abbvie, Astellas, Bristol‐Myers Squibb, Gilead, Merck Sharp & Dohme and Novartis, and he has received research funding from Gilead. Ricardo Baptista‐Leite has nothing to declare. Charles Boucher has received research grants ViiV, Merck, Gilead; Speaker fee Gilead, ViiV; Research grant Gilead sciences and co‐owner Virology Education. Cristian‐Silviu Busoi has nothing to declare. Sylvie Deuffic‐Burban has received grants from ARHEL (2015‐2016) and MSD (2017); has served on advisory boards for Abbvie (2015), BMS (2015), Gilead (2015) and MSD (2016‐2017); and reports lecture fees for Abbvie (2018), BMS (2015) and Gilead (2017), outside the submitted work. Jagpreet Chhatwal has received research grants and personal fee from Gilead and Merck outside the submitted work. Gamal Esmat has nothing to declare. Sharon Hutchinson has received honoraria for presenting at a conference sponsored by Gilead. Minerva ‐Melpomeni Malliori has nothing to declare. Mojca Maticic has nothing to declare. Antons Mozalevskis has nothing to declare. Francesco Negro has received research grant funding from Gilead, and is Advisor/Consultant for Gilead, Merck and AbbVie. George A. Papandreou has nothing to declare. George V. Papatheodoridis has served as advisor/lecturer for Abbvie, Bristol‐Myers Squibb, Dicerna, Gilead, GlaxoSmithKline, Ipsen, Janssen, Merck Sharp & Dohme, Novartis, Roche, Spring Bank; research grants Abbvie, Bristol‐ Myers Squibb, Gilead, Janssen, Roche. Markus Peck‐Radosavljevic has received grants from Gilead and MSD, honoraria for consulting/lectures from AbbVie, Boehringer Ingelheim, Bristol‐Myers Squibb, Gilead, Janssen and MSD. Homie Razavi has received grants from CDC Foundation, John Martin Foundation, ASTHO, Zeshan Foundation, and other Private donors. In addition, his organization has received funding from Gilead Sciences, AbbVie, Intercept Pharma, and Vaccine Impact Modeling Consortium. He is the managing director of Center for Disease Analysis and Center for Disease Analysis Foundation. Tatjana Reic has nothing to declare. Eberhard Schatz as C‐EHRN receives funding for HCV‐related work by GILEAD Science and Abbvie. Nurdan Tozun has nothing to declare. Zobair Younossi received consulting fees or funds for research support from Allergan, Bristol‐Myers Squibb, Gilead Sciences, Intercept, Novartis, Novo Nordisk and Shionogi. Michael P. Manns has been principal investigator and he has received grants/advisor/lecturer/travel support from Abbvie, Bristol‐Myers Squibb, Gilead, Janssen, Merck Sharp & Dohme. 1 Funding Information: David Tordrup, WHO Collaborating Centre for Pharmaceutical Policy and Regulation University of Utrecht, Netherlands. The authors thank Ann Fox for her valuable contribution towards the success of the conference. The financial support of Gilead Sciences, Abbvie and Merck Sharp & Dohme is gratefully acknowledged Funding Information: Funding information David Tordrup, WHO Collaborating Centre for Pharmaceutical Policy and Regulation University of Utrecht, Netherlands. The authors thank Ann Fox for her valuable contribution towards the success of the conference. The financial support of Gilead Sciences, Abbvie and Merck Sharp & Dohme is gratefully acknowledged Publisher Copyright: {\textcopyright} 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd",
year = "2020",
month = feb,
day = "1",
doi = "10.1111/liv.14282",
language = "English",
volume = "40",
pages = "260--270",
journal = "Liver International",
issn = "1478-3223",
publisher = "Wiley",
number = "2",
}